UK biotech Mereo BioPharma is attempting to face down a revolt by Rubric Capital Management – its largest shareholder holding around 14% of the company – which is agitating for changes to i
With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID.